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Abstract 
Background: Schizophrenia is a severe mental disorder that affects 1 % of the world’s population, including 600,000 
people in France. Persons with schizophrenia (PWS) have excess mortality (their life expectancy is reduced by 20 %) 
and excess morbidity. In addition, such persons may have a large number of missing or decayed teeth. Dental caries 
and periodontal measurement indexes are often twice as high as the level found in the general population. Poor oral 
health can also affect quality of life and oral health is inseparable from general health. The management of oral health 
problems needs a multidisciplinary approach. According to the World Health Organization, the aim of therapeutic 
education (TE) is to help patients take care of themselves and to improve empowerment and recovery. In this educa‑
tional approach, it is important to take into account the patient’s personal experience. Though rarely investigated, the 
personal experience of PWS in oral health quality of life (OHRQoL) must be used to build a therapeutic educational 
programme in oral health (TEPOH) in a multidisciplinary approach, and the effectiveness of this program must be 
evaluated.
Methods/design: We report the protocol of a randomized controlled cluster study. This study will be conducted in 
twelve hospitals in France. We hypothesized that a decrease of 20 % in the proportion of patients with CPI ≥ 3 would 
establish the effectiveness of TEPOH. Therefore, 12 hospitals will be randomly allocated to either TEPOH or no TEPOH. 
Altogether, they will have to recruit 230 PWS, who will be randomly allocated with a ratio of 1:1 to one of two condi‑
tions: control without intervention versus the group benefitting from TEPOH.
Discussion: If successful, the study will generate methodologically sound results that provide knowledge on the 
effectiveness of a TEP in oral health for PWS. The results can be used to promote OHRQoL in a global health approach 
and develop appropriate strategies to encourage and facilitate financial support for healthcare, the multidisciplinary 
treatment of dental disorders, and the development of training in oral and mental health for caregivers.
Trial registration Clinical Trials Gov NCT02512367. Date registered 19 July, 2015
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Background
Schizophrenia is a severe mental disorder that affects 
1  % of the world’s population [1, 2], including 600,000 
people in France. Schizophrenia is characterized by a 
set of different symptoms varying in intensity: the most 
dramatic are delusions, hallucinations, mental dissocia-
tion, and, for the most handicapping, social withdrawal, 
denial of the body, and cognitive difficulties [3]. Persons 
with schizophrenia (PWS) have excess mortality (their 
life expectancy is reduced by 20 %) and excess morbidity 
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health has been reported by many authors and contrib-
utes to the overall poor health of these patients [6–8]. 
Generally, the symptoms of schizophrenia lead to distur-
bances in the progression of thought, errors in contextual 
analysis and errors of logic. Often, PWS do not recognize 
their health needs and delay seeking advice or treatment 
[9].
This is the case for all related somatic disorders that, by 
lack of analysis inherent to this disease, prevent the per-
sons from recognising the condition or cause them not to 
make the right decisions to solve problems independently 
[9, 10]. Moreover, difficult relationships with professional 
caregivers (fear of mental illness, lack of training) and 
the health system in general (difficulties in gaining access 
to private practice, environment, cost…) are additional 
obstacles contributing to deficient somatic care [11, 12].
One of the most visible elements of poor oral health 
is edentulousness, and a large number of missing or 
decayed teeth (leading to pain, infection, masticatory 
and digestive problems) can be noticed in this population 
[13, 14]. Dental caries, periodontal or infectious diseases 
on the one hand, and metabolic disturbances induced 
by antipsychotic treatments (diabetes, obesity, xeros-
tomia…), poor diet and lifestyle behaviours (diet rich in 
sugars, use of psychoactive substances such as tobacco, 
and inadequate oral hygiene), all combine to lead to poor 
health [14–16].
Generally, negative symptoms, age, duration of men-
tal illness, xerostomia, low socio-economic and cultural 
determinants are risk factors common to tooth decay and 
periodontal disease [17–21]. These factors are aggravated 
by stigmatization and discrimination, which is why PWS 
do not have the same amount of attention, in terms of 
their physical health, as others [22, 23]. International data 
confirm that oral health is poor in PWS. Dental caries and 
periodontal measurement indexes are often twice the level 
found in the general population [8, 14, 20, 21]. Generally 
speaking, less than 10 % of the population of industrialized 
countries suffer from severe forms of periodontitis [24, 
25]. Periodontal health is assessed using different indexes. 
The periodontal index, called the CPI (community perio-
dontal index), is the World Health Organization’s (WHO) 
reference index [26]. It is estimated that 40 % of schizo-
phrenics exhibit a CPI ≥ 3 according to the literature [27, 
28]. A CPI  ≥  3 indicates advanced periodontal disease, 
with a loss of alveolar bone depending on severity. The 
most consistent predictors of periodontal disease are age, 
education, income, smoking status, dental visits, the num-
ber of remaining teeth, the number of decayed coronal 
surfaces, the number of decayed root surfaces and diabe-
tes. Periodontal disease is therefore influenced by medi-
cal, social and behavioral factors [29, 30]. Appropriate 
treatment to control periodontal infection can limit the 
number of affected sites and stop the progression of the 
disease [31]. For the management of oral health problems, 
it is important to control the frequency of daily brushing 
and the side effects of antipsychotic treatments, to ensure 
regular dental visits and to monitor the respect of dental 
hygiene advice [32].
Poor oral health can also affect quality of life through 
the social and psychological impact of the deterioration 
in smile aesthetics for self-esteem, and self-confidence 
[8, 22]. The oral side effects of antipsychotics generally 
include a reduction in the salivary flow rate. Conversely, 
Clozapine can induce hypersalivation. However, a dry 
mouth was the chief complaint among 40 % of the psy-
chiatric patients while dental pain was the main com-
plaint among 60 % of the control group [33].
There are also the neurological effects of first-genera-
tion antipsychotics (FGAs) (dystonia, dyskinesia), which 
produce shaking and prevent effective brushing, alter 
chewing and swallowing [34, 35]. Second-generation 
antipsychotics (SGAs) induce more metabolic side effects 
and fewer neurological effects [36, 37]. Evidence of a rela-
tionship between metabolic disorders and oral deficien-
cies has gradually grown over the last 10 years with, on 
the one hand, increased knowledge on the pathophysiol-
ogy of the syndrome and its consequences on cells and 
tissues and, on the other hand, the observation that cer-
tain infectious diseases of the mouth, such as periodon-
tal disease, have already been associated with each of the 
components of the metabolic syndrome [38]. This means 
that diabetes is a risk factor for the development of peri-
odontal disease. Control of periodontal infection would 
furthermore contribute to controlling diabetes [39–41]. 
Periodontal disease is also a risk factor for cardiovas-
cular diseases (ischemic heart disease) and associated 
with excess mortality in PWS. One explanation is that 
poor oral hygiene allows oral bacteria to enter the blood-
stream. Immune complexes are then formed, which, in 
turn, elicit inflammatory responses in arteries [42, 43]. 
Furthermore, oral health is not just about having healthy 
teeth, it is a ‘standard of health of the oral and related tis-
sues which enables an individual to eat, speak and social-
ise without active disease, discomfort or embarrassment 
and which contributes to general well-being’. Oral health 
is thus inseparable from general health, and managing 
oral health problems needs a multidisciplinary approach. 
Currently, oral health prevention and promotion pro-
grams, based on knowledge in the general population 
and transposed for persons with severe mental disorders, 
have not proven to be very effective [44–46]. The par-
ticular profile of persons suffering from schizophrenia 
must be taken into account. Khokhar et al. [45] pointed 
out that there were no studies with a high enough level of 
proof to support current practices in this field.
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The research deals with ways to help persons with 
smoking, a sedentary lifestyle, unbalanced diet, and dental 
health status [47–49]. This requires people, especially the 
family circle, social, medical and social services person-
nel, private nurses and general practitioners [50–52], to 
be trained to interact frequently with such patients. This 
training is particularly necessary because healthcare pro-
fessionals often have an aversion to these patients (fear of 
the mental illness, lack of training), leading to numerous 
biases and generating an unhelpful attitude. The lack of 
initial training in this field contributes to misunderstand-
ing among caregivers and the stigmatization of patients 
suffering from schizophrenia [12, 52]. It is therefore 
important not only to build awareness of oral health prob-
lems in PWS, but also to train these caregivers in psychi-
atric diseases. The aim of this training would be to foster 
better understanding of patients’ symptoms in order to 
avoid misunderstandings regarding their behaviour.
In response to the increased prevalence of chronic dis-
eases, the very high rate of treatment non-observance, 
and the need for more personal autonomy, therapeutic 
education (TE) with small groups (five or six partici-
pants) is gradually emerging as a healthcare approach 
[53, 54].
For example, Lindenmayer et  al., showed the effec-
tiveness a structured wellness program using a psy-
choeducational curriculum for weight reduction and 
other metabolic markers in a large inpatient sample (275 
patients with severe mental illness) [55].
According to the World Health Organization (WHO), 
the aim of TE is to help patients take care of themselves 
and to improve empowerment and recovery [54]. In this 
educational approach, it is important to take into account 
the experiences of persons taking part in multidiscipli-
nary group learning. In a preliminary study, we confirmed 
the acceptability and feasibility of partnerships with PWS 
to develop an interactive guide to improve access to pri-
mary care providers for chronic disease management and 
health promotion [56]. TE is too often limited to cogni-
tive information or movement training. Health beliefs 
are often not studied and the presentation of the causal 
links between inadequate behaviour and chronic disease 
is largely insufficient to treat a patient successfully over 
the long term [57, 58]. A new approach to TE programs 
depends on a specific environment to foster motiva-
tional behaviour change, not only “focused” on patients 
but developed with them. In this model, the person is the 
best expert of the disease. In the TE concept, as partici-
pants themselves are trying to learn, one can explore not 
only what the participants are talking about, but also how 
they are trying to understand and conceptualize the issue 
under discussion [59, 60].
Rarely investigated, the PWS experience in oral health 
quality of life (OHRQoL), must be used to build an edu-
cational therapeutic program in oral health in a small 
multidisciplinary group learning process.
Aims
The principal objective of this study is to evaluate the 
effectiveness of a therapeutic education programme in 
oral health (TEPOH) for PWS. This aim will be achieved 
in the context of a randomized controlled cluster study 
using a population with schizophrenia sample recruited 
from out- or in-patients in psychiatric hospitals in 
France.
We hypothesize that a multidisciplinary therapeutic 
education program (TEP), involving dentists, psychia-
trists, nurses, doctors, psychologists, PWS, caregivers 
and specialists in therapeutic education, will promote 
clinical improvements in oral health. In addition, we will 
assess TEPOH as a new care support strategy for improv-
ing the oral health related quality of life (OHRQoL) of 
PWS. We will also assess caregiver’s behavioural changes 
concerning oral health in PWS.
Methods/design
It is a multicentre, cluster randomized controlled trial 
designed to assess the effectiveness of a TEPOH on PWS. 
Therefore, 12 hospitals will be randomly allocated to four 
clusters (a cluster is composed of three hospitals) where 
benefiting from TEPOH is available or not, and 230 PWS 
will be recruited and randomly allocated with a ratio of 
1:1 to one of two conditions: control without interven-
tion versus the group benefitting from TEPOH.
Study process (Fig. 1)
Preliminary stage
Building a therapeutic educational program in oral health 
(Fig. 2). A preliminary phase of this study will consist of 
the creation of the program content. An expert group 
made up of health professionals, stabilized PWS, and car-
ers of PWS has been created. A focus group (FG) led by 
a specialist in TE “Instance Régionale d’éducation et de 
promotion de la santé” (IREPS) explored the needs and 
expectations in oral health among PWS [61]. Participants 
were able to defend their priorities, preferences, values 
or experiences. The FG method is generally used to col-
lect opinions, beliefs and attitudes about a topic or issue 
and to encourage the discussion of particular problems 
[62, 63]. After three FG targeted on oral health, problems 
in PWS were identified and summarized in the form of 
a questionnaire. These semi-structured questionnaires 
were presented by the same methodology to two dis-
tinct groups (composed of different people of the expert 
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group): A group composed of health professionals only 
and a group of PWS and carers of patients. After a pro-
cessing step of collecting information, the expert groups 
met again to validate the themes chosen for the construc-
tion of TEPOH program and the educational tools neces-
sary for its implementation.
The different chosen themes are:
1. Mobilization of motivational approaches by improv-
ing self-esteem and well-being, entitled:  «  Yes we 
can »
2. Demystifying the dental surgery entitled:  «  Even 
more afraid »
3. Improvement of oral health by a transverse approach 
(stop smoking, control diabetes, management of 
good diet…) to quality of life entitled: « Take care of 
myself »
Ultimately, the TE program will consist of three work-
shops, an introductory session and a debriefing session 
each lasting 90 min, spaced 2 weeks apart: A report form 
to allow patients to collect their behaviour changes with 
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Results analysis 
TEP in control cluster 
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Fig. 1 Study flow diagram. Asterisk 12 co‑investigators, members of the expert group, a methodologist and statistician. Double asterisk Instances 
régionales d ‘éducation et de la promotion de la santé
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respect to oral health (improving oral hygiene, reducing 
tobacco use, attitudes of caregivers and others…) will be 
given to participants.
Before the three phases of the TEPOH, an introductory 
session will be conducted. It will consist of a presentation 
of the TEPOH and an exploration of OHRQol represen-
tations. It will be performed collectively with participat-
ing patients in the presence of their accompanying carers. 
Information will be collected using the metaplan method 
[64]. At the end of the TEPOH sessions, a second meet-
ing will be conducted in order to carry out a compara-
tive qualitative analysis with participating patients in the 
presence of their accompanying carers.
Finally, the time required for the TEPOH will be 7.5 h 
not counting the time for the baseline and follow-up 
assessments. Finally, the program will last 2 months.
This program has been designed for groups of five or 
six participants. The entire program will be pretested 
before its initiation according to the clinical study proto-
col on a pilot institution with a cluster not involved in the 




Table  1 summarizes the criteria used to determine the 
eligibility of participants. A potential participant must 
have been diagnosed with schizophrenia as defined in 
the Diagnostic and Statistical Manual of Mental Disor-
ders-Fifth edition (DSM-5) [65] and be receiving in- or 
outpatient care in one of the hospitals taking part in the 
study. Potential participants, over 18 years of age, can be 
of either sex. Schizophrenia is a severe mental disorder 
characterized by a set of different symptoms varying in 
intensity [3]. Persons not stabilized from a psychiatric 
viewpoint will be excluded. Persons will be excluded if 
hospitalized under stress or the person does not perceive 
the significance of the study or is not motivated to take 
care of their oral health. We will exclude people with 
severe somatic disorders regarding the aims of the study 
so as not to generate management problems of health 
care. Finally, we will exclude edentulous persons, because 
the absence of teeth is a limitation of our TEPOH for our 
end-point (periodontal disease) and temporarily for per-
sons who have not updated their social rights to cover 
the cost of medical and dental care. In France, medi-
cal and dental care costs are covered by national health 
Expert group*










Etape 1 « Yes we can »
Etape 2 « Even more afraid »






















Program test on pilot hospital
Fig. 2 Therapeutic education program flow. Asterisk two dentists, 
three schizophrenic persons stabilized from a psychiatric viewpoint, 
one psychologist, one psychiatrist, two mental health nurses, one 
doctor, 2 patient aides. Double asterisk three schizophrenic persons, 
three accompanying patients. Triple asterisk one doctor, one dentist, 
one psychlogist, two nurses, one psychiatrist
Table 1 Inclusion and exclusion criteria
a Persons with prosthetic valve, cyanotic congenital heart disease, history of infectious endocarditis
Inclusion criteria Exclusion criteria
Persons who have provided consent Persons not covered by national health insurance
Persons of either sex over 18 years of age Persons not stabilized from a psychiatric viewpoint or persons in an acute 
psychiatric episode
Persons with diagnosis of schizophrenia as defined in the Diagnostic and 
Statistical Manual of Mental Disorders‑Fifth edition (DSM‑5)
Pregnant or breast‑feeding women
Edentulous persons
Persons hospitalized under stress
Receiving care in hospital (in‑ or outpatient) Cannot understand or have a poor understanding of French
Patients with risk of infective endocarditisa or major risk of superinfection
People undergoing chemotherapy
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insurance and complementary health insurance or by 
universal health insurance (CMU) depending on the level 
of income. For people with low incomes, below 7771€ per 
year, CMU is free [66]. Indeed, as the aim of the program 
is to motivate participants to improve their oral health, if 
a participant does not have financial resources to access 
the health care system, the programme will be counter-
productive. PWS have less access to dental care because 
of its cost. This problem must be solved before their 
inclusion in the study.
Recruitment procedures
In 1960, France opted for mental health care based on 
the definition of local catchment areas. The country was 
divided into sectors of approximately 70,000 inhabitants 
[67]. Each sector is run by a reference hospital and a mul-
tidisciplinary team intended to provide preventive, as 
well as curative and rehabilitative care for all those within 
the catchment area who need it. Care is provided as close 
to home as possible. Patients can only have ongoing con-
tact with the psychiatric sector’s outpatient unit and live 
in the community or can be hospitalized depending on 
severity their mental disorders [67]. The 12 hospitals that 
will take part in the study cover 42 psychiatric sectors. 
There are potentially 2,940,000 inhabitants and about 
29,400 PWS for recruitment in the study. The local catch-
ment areas of the 12 psychiatric hospitals are sufficiently 
distant from each other. The two closest hospitals are 
60 kms apart, and the farthest are 600 kms apart. The 12 
hospitals participating in the study are spread over the 
eastern half of France.
To maximize recruitment, co-investigators will pro-
vide information on the study in the different hospitals. 
They will inform potential participants about the study 
by means of the internal communication system for car-
egivers of the institution (e-mail or newsletter) and via 
the distribution of flyers informing PWS about the study. 
Those who express an interest will be given details of the 
study and screened for their eligibility by the study team 
of the co-investigator. All participants (caregivers and 
PWS) will be aware that the study relates to an assess-
ment of the effectiveness of TEPOH and the exact nature 
of the research project (i.e., the existence of the interven-
tion and control groups and the comparison of outcomes 
between them). Upon debriefing at the end of the study, 
the PWS who were in the no-TEPOH group could benefit 
from TEPOH.
Participants may withdraw from the trial either at their 
own request or at the discretion of the Investigator (acute 
psychiatric disorders). Participants will be made aware 
that withdrawal will not affect their future care. All par-
ticipants (PWS and caregivers) will be made aware (via 
the information sheet and consent forms) that should 
they withdraw, the data collected to date cannot be 
erased and may still be used in the final analysis.
Procedure
In the first phase, hospitals will be randomized and 
groups of five or six participants will be organized. Ran-
domization will be collective between the hospitals and 
not between patients. The local catchment areas of the 
12 psychiatric hospitals are sufficiently distant from each 
other to avoid a bias of contamination between individu-
als of the same hospital. The trial will be conducted in the 
open because it is not possible to assess a person’s oral 
health without the person and the operator knowing. 
Cluster randomization is recommended by the “la Haute 
Autorité de Santé” (HAS) in France for evaluation trials 
of interventions to improve practices.
In the second phase, patients able to participate in the 
study will be screened in each local catchment area. Con-
senting participants will be contacted to arrange an oral 
health assessment. Evaluations will be conducted at the 
outpatient unit or at the hospitals where the patients are 
followed. Prior to arriving in their TEPOH group, they 
will be asked to complete a battery of psychological and 
OHRQoL questionnaires. Participants’ socio-economic 
status (SES) will also be collected.
In the third phase, participants will undergo a battery 
of tests to assess their oral health disorders using clinical 
and radiological examinations. At the end of this step, the 
TEPOH will be performed or not depending on the clus-
ter to which the PWS belongs.
Before the start of the TEPOH, the teams of caregiv-
ers for the patients will be invited to participate in a focus 
group interview to assess their knowledge of oral health 
and their practices in the management in OHrQOL with 
PWS.
The fourth phase will consist of an evaluation at 3 
months, 6 months and at 1 year after the initiation of 
TEPOH. All participants (patients and caregivers) will 
be asked to complete the same battery of tests they com-
pleted at baseline except for radiological examinations 
and SES.
The interviews for the OHRQoL will be managed to 
ensure that participants in the two groups (control vs 
TEPOH group) do not interact with each other.
Interventions
All participants at the twelve sites will be interviewed and 
clinically examined by the co-investigators.
Demographic and medical variables were extracted 
from institutional medical records: diabetic or not, pre-
scribed drugs at the time of the examination, duration of 
mental illness. Other variables, namely the level of edu-
cation, residential area, smoking habits, tooth brushing 
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frequency and last dental visit, were collected directly by 
questioning the patient. Each participant will be asked to 
complete the French version of global oral health assess-
ment index (GOHAI) [68], the schizophrenia quality of 
life questionnaire (S-QOL) [69], the Beck Depression 
Inventory-(BDI-II) [70], the stability status of symptom 
severity scale (PANSS) [71] and to answer other ques-
tions relating to their SES, health status (duration of 
mental illness), dental attendance and oral behaviour 
(smoking habits, tooth brushing frequency).
In a second time, each person will undergo a clinical 
oral examination in the dental surgery of the hospitals 
participating in the study. Pre-packaged and disposable 
instruments—dental mirrors, tweezers, 0.5  mm ball-
ended CPITN probes (3.5–5.5  mm)—will be used and 
cotton rolls will be used to remove plaque. Caries will be 
assessed at the dentinal (D3) level using the DMFT index 
[72]. Dental plaque and calculus will be evaluated using 
the simplified oral hygiene index (OHI-S) [73] and peri-
odontal disease by the community periodontal index of 
treatment needs (CPITN) [26].
This investigation will require 1 h for each participant. 
At the end of this evaluation, the TEPOH could start, as 
described previously, in all clusters selected for the study.
The mental health of PWS will be closely monitored by 
their care teams, and care co-investigators will be asked to 
inform the trial team of any adverse event that either the 
care co-ordinator or patient notices. The trial team will 
determine the seriousness and causality in conjunction 
with treating medical practitioners. Serious adverse events 
are divided into two categories, those that seem likely to be 
independent of TEPOH and those connected with TEPOH. 
All adverse events will be recorded and closely monitored 
until resolution, stabilization, or until it has been shown 
by the data monitoring committee that involvement in the 
trial is not the cause. All treatment-related serious adverse 
events will be recorded and reported to the Research Eth-
ics Committee (REC) as part of the annual reports. Unex-
pected serious adverse events will be reported to the REC 
by the chief investigator, who will take appropriate medical 
action, which may include halting the trial and informing 
the sponsor of such action. Any participant who experi-
ences an adverse event may be withdrawn from the study at 
the discretion of the investigator.
Control
Participants assigned to the control condition will be 
advised to maintain their existing lifestyles or take on 
new activities as they see fit. They will be examined only 
at the clinical evaluation at the start of the study and at 
3, 6 and 12 months. For ethical reasons, if the program 
shows its effectiveness, it will be made available to all 
groups at the end of the study.
Outcomes
Our primary end-point will be the impact on periodon-
tal disease. We have chosen periodontal index for our 
primary outcomes. Indeed, periodontal diseases are in 
relation with predictor in oral health (medical and dental 
condition, behavioural and SES) [29, 30].
The community periodontal index of treatment needs 
(CPITN) will be used to assess the periodontal status 
of the participants in the survey [26]. With the help of 
a World Health Organization periodontal probe, the 
depth of the periodontal pocket will be measured at six 
points on both the buccal (facial) and (lingual or palatal) 
surfaces of the index teeth. This measure will be used to 
score periodontal status and assess patients’ treatment 
needs. The initial sign of periodontal disease is bleed-
ing of the gums. As it progresses, the gum retracts from 
the root surface of the tooth to form pockets. The deeper 
the pocket, the more severe the periodontal disease. The 
CPITN is a 5-point scale graduated as follows: no sign 
of periodontal disease (0), gingival bleeding after gen-
tle probing (1), supragingival or subgingival calculus (2), 
pathological pockets 4–5 mm deep (3) and pathological 
pockets >5 mm deep (4).
The secondary end point will be impact on caries meas-
ured by the DMFT score [72]. Decay will be assessed 
using this standardized index to evaluate existing or 
past dental caries with scores ranging from 0 to 32. This 
examination will assess dental caries, dental restorations, 
fissure sealants, fixed prostheses, missing teeth and an 
additional category for traumatized incisors. High scores 
indicate worse dental health [72]. Root caries will not be 
assessed in this study.
Other secondary evaluation criteria will include a 
hygiene index. The debris index component of the sim-
plified oral hygiene index (OHI-S) [73]. This tool will be 
used to measure the amount of debris. It will be scored 
on six tooth surfaces per participant.
For all of the dental examinations above, the dental spe-
cialists have been calibrated against the chief investigator, 
through repeated examinations of a separate pilot sample 
using similar indices, followed by meetings to discuss dis-
crepancies and standardize procedures. Kappa scores of 
0.9 for inter-rater agreement were achieved.
The following four tools will be used in this study: The 
OHRQoL from the French version of the self-assessment 
GOHAI scale [68]; schizophrenia quality of life from 
S-QoL [69]; The stability status of symptom severity from 
the PANSS scale [71] and depressive symptoms of schiz-
ophrenic persons from the Beck Depression Inventory 
scale [70].
Finally, a panoramic radiograph will be done if 
the patient does not have radiographs dating back 
less than 3  months. The dental panoramic film 
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(orthopantomogram) is to detect periodontal disease, 
fractures, tumours and bone disorders from teeth and 
conditions that may affect the jaw and sinuses. A quali-
tative analysis of data collected during the TEPOH will 
make it possible to determine the evolution of represen-
tations, knowledge, attitudes and the practices of patients 
and professionals, and the ability of patients and profes-
sionals to assimilate an educational process.
Sample/randomization and data‑management
The literature highlights that up to 40  % of PWS disor-
ders have a mean CPI ≥  3 [27, 28], compared with less 
than 10  % in general population [24, 25]. Anticipating 
that the TEPOH will lead to a mean 20 % reduction in the 
CPI index of patients, taking into account cluster vari-
ability (CV =  0.37) and the intra-class correlation coef-
ficient (CCI = 0.01), we will have to recruit a total of 202 
patients to highlight a statistically significant difference 
between the two groups with a type-I error of 5  % and 
type-II error of 20 %.
Randomization will be done using SAS version 9.3 
(SAS Institute Inc) by the team of statisticians of the 
Methodological Support Unit, Direction of Clinical 
Research, UHD, France. All participating hospitals will 
be randomly allocated to TEPOH or not using a random 
stratified sampling method depending on their location 
(urban/mixed/extra-urban) and their level of activity 
(number of patients per year). All data of included per-
sons will be collected in an electronic case report form 
(CRF), created with the software CleanWeb™. Real-time 
likelihood and coherency tests will be implemented to 
check data entry with predefined rules in collaboration 
with all the co-investigators. Periodically, coherence 
reports will be sent to investigators with the aim to cor-
rect any highlighted errors. The database will be frozen 
only when all of the errors have been corrected and 
when no more are found.
Statistical analysis
The interview data will be transcribed and coded using 
NVivo software to facilitate analysis of the factors identi-
fied by participants as affecting their attitudes and behav-
iours relating to changes in perception in OHRQoL. This 
process will yield a comprehensive account of the relevant 
barriers, motivators, and facilitators of OHRQoL. Among 
the intervention group participants, changes in attitudes 
will be documented. Results for qualitative covariates will 
be expressed as proportions. Quantitative variables will 
be expressed as means ± standard deviations (SD) when 
normally distributed, or as medians and ranges in other 
cases. Comparison of persons’ characteristics between a 
group of interest and the general population of PWS will 
be performed using Student’s t test, analysis of variance, 
Kruskal–Wallis non-parametric tests and Pearson’s Chi 
square or Fisher’s exact test when appropriate. A value 
of p < 0.05 will be considered statistically significant. All 
analyses will be performed using SAS version 9.3 (SAS 
Institute INC.).
Electronic data will be stored on secure data servers 
and hard copy materials will be retained in locked filing 
cabinets of Dijon University Hospital.
Discussion
Innovation
This document provides a complete description of the 
construction, the use and evaluation of the effective-
ness of TEPOH specifically designed for PWS with their 
active participation for the first time.
The current study is innovative because it proposes to 
investigate the impact of a strong partnership between 
PWS and their caregivers to improve their oral health in 
France.
This TEPOH can be used to promote OHRQoL in a 
global health approach and to develop appropriate strat-
egies to encourage and facilitate financial support for 
healthcare, the multidisciplinary treatment of dental dis-
orders, prospective support for patients, and the develop-
ment of training in oral or mental health for caregivers.
Limitations
The active participation of patients is a key component of 
the study. However, the major difficulties with the inclu-
sion of PWS in a long-term protocol study is that many 
PWS may be unable to cooperate due to their psychiatric 
illness, or lost to follow-up, or die during the study.
Secondly, although oral health has an impact on gen-
eral health, self-esteem and quality of life often have a low 
priority in persons with psychiatric diseases in France. 
Furthermore, the somatic care of patients undergoing 
psychiatric treatment remains heterogeneous.
In this case, a key component will be the participa-
tion and involvement of healthcare teams in introducing 
TEPOH in their practices and in promoting TEPOH in 
all units of the hospital.
Impact
Finally, this study is needed to inform the development 
of public policy and interventions that have the potential 
to improve the OHRQoL of PWS and the feasibility to 
engage PWS as full partners in TEPOH.
Trial status
The preliminary phase of the study is completed and data 
collection for patients is closed. We will proceed with 
randomization of the clusters and will include the first 
patients in the study during July, 2016.
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